Humoral and T-cell-mediated immunity to SARS-CoV-2 vaccination in patients with liver disease and transplant recipients.
Alexandra N WillauerSusan D RousterHeidi L MeedsCarrie L JenningsEnass A Abdel-HameedDiane E DariaElizabeth P StambrookMohamed Tarek M ShataKenneth E ShermanPublished in: Hepatology communications (2023)
The immunogenicity of the SARS-CoV-2 vaccine is complex and multifactorial. Ongoing and longitudinal evaluation of SARS-CoV-2 humoral and cellular responses is valuable and necessary to allow frequent re-evaluation of these patient populations.